Appili Signs Manufacturing Deal

Halifax-based Appili Therapeutics Inc. has signed a manufacturing agreement for one of its drug candidates that could become a vaccine used to combat biological warfare.
The company, which is developing anti-infective drug candidates, issued a statement Tuesday saying it has signed a partnership with Alachua, Fla.-based Ology Bioservices to manufacture Appili’s drug candidate ATI-1701.
The U.S.